A 2026 mechanistic study involving 28 healthy adults found that a single 25 mg psilocybin session changed acute brain entropy, psychological insight, well-being, cognitive flexibility, and some MRI-derived white-matter signals for up to 1 month. Research Highlights Acute brain entropy rose clearly: 25 mg psilocybin increased Lempel-Ziv complexity (LZc; a measure of signal irregularity) at …
A 2026 study involving 32 adult mangrove rivulus fish pairs found that 3,000 µg/L waterborne psilocybin reduced movement and aggressive swimming bursts, but the result belongs in animal behavioral pharmacology, not in human aggression treatment claims.1 Research Highlights Fish movement decreased: psilocybin produced a treatment-by-time interaction for time spent moving (p = 0.006), with a …
A 2026 eLife computational study modeled classical psychedelics by increasing a network state variable from alpha = 0 to alpha = 1, shifting perception from bottom-up sensory inference toward top-down generative replay. The result is a useful but still unproven oneirogen model: hallucinations look less like random noise and more like wake-time replay of a …
Media coverage of psychedelics outpaces the trial evidence. MDMA-PTSD signals are large; psilocybin-depression effects shrink against active comparators.
The intersection of mental health treatment and pharmacology is witnessing a remarkable shift with the growing interest in ketamine and classic psychedelics like psilocybin for their rapid and sustained antidepressant effects. Unlike traditional antidepressants, these substances offer hope for those with treatment-resistant depression by potentially transforming treatment paradigms. However, it remains somewhat unclear as to …
In the quest for innovative treatments for psychiatric disorders, the study of psychedelics has taken a significant leap forward. Among these, Dimethyltryptamine (DMT), known for its rapid onset and short duration of action, emerges as a compelling alternative to traditional therapies. Recent studies have begun to explore its potential, particularly in treating depression and anxiety, …
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …